Valuation: Theraclion

Market Cap 4.46Cr 5.15Cr 4.16Cr 3.82Cr 7.22Cr 489.61Cr 7.3Cr 49Cr 19Cr 244.98Cr 19Cr 19Cr 811.34Cr P/E 2024
-2.66x
P/E 2025 -6.33x
Enterprise Value 5.24Cr 6.06Cr 4.89Cr 4.5Cr 8.49Cr 575.81Cr 8.58Cr 57Cr 23Cr 288.11Cr 23Cr 22Cr 954.19Cr EV / Sales 2024
22.5x
EV / Sales 2025 55.4x
Free-Float
54.37%
Yield 2024 *
-
Yield 2025 -
1 day-3.55%
1 week+2.70%
Current month+5.17%
1 month-1.89%
3 months+29.25%
1 week 0.54
Extreme 0.542
0.59
1 month 0.54
Extreme 0.542
0.65
Current year 0.44
Extreme 0.436
0.93
1 year 0.44
Extreme 0.436
0.93
3 years 0.44
Extreme 0.436
0.93
5 years 0.44
Extreme 0.436
0.93
10 years 0.44
Extreme 0.436
0.93
Manager TitleAgeSince
Chief Executive Officer - 24/05/2023
Director of Finance/CFO - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member - 01/02/2018
Director/Board Member - 13/02/2019
Director/Board Member - 13/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-3.55%+2.70% - - 5.15Cr
-0.82%-0.77%+27.48%+3.72% 21TCr
-0.77%+0.93%+1.45%-22.54% 14TCr
-0.80%+5.71%-21.29%+20.66% 13TCr
+3.85%+7.72%-51.87%-2.33% 6.92TCr
-0.62%+1.82%+12.59%+10.85% 5.13TCr
-0.31%+5.24%-14.16%-19.76% 5.04TCr
-1.01%+1.02%+23.75%+10.76% 3.99TCr
-1.79%+3.85%+42.22%+36.32% 3.93TCr
+0.12%+7.55%-20.02%+20.16% 3.23TCr
Average -0.56%+3.77%+0.02%+6.43% 8.54TCr
Weighted average by Cap. -0.33%+3.04%+2.02%+2.96%

Financials

2024 2025
Net sales 8L 10L 8L 7L 13.44L 9.11Cr 13.59L 90.94L 35.69L 4.56Cr 36L 35.21L 15Cr 7L 8L 6L 6L 10.55L 7.16Cr 10.67L 71.42L 28.03L 3.58Cr 28.27L 27.65L 12Cr
Net income -57.57L -66.47L -53.67L -49.36L -93.18L -63Cr -94.22L -6.31Cr -2.48Cr -32Cr -2.5Cr -2.44Cr -104.74Cr -56.9L -65.7L -53.04L -48.78L -92.1L -62Cr -93.13L -6.23Cr -2.45Cr -31Cr -2.47Cr -2.41Cr -103.52Cr
Net Debt 34.11L 39.38L 31.79L 29.24L 55.2L 37Cr 55.82L 3.74Cr 1.47Cr 19Cr 1.48Cr 1.45Cr 62Cr 78.52L 90.66L 73.19L 67.32L 1.27Cr 86Cr 1.29Cr 8.6Cr 3.38Cr 43Cr 3.4Cr 3.33Cr 142.85Cr
Logo Theraclion
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.
Employees
36
Date Price Change
06/26/06 0.5700 -3.55%
05/26/05 €0.5910 0.00%
04/26/04 €0.5910 +9.04%
03/26/03 €0.5420 0.00%
31/26/31 €0.5420 -2.34%

Annual profits - Rate of surprise